U.S. Markets close in 14 mins

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RBGLY, NGHC, MNK and EVH

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Reckitt Benckiser Group plc (RBGLY)
Class Period: On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019
Lead Plaintiff Deadline: September 13, 2019

Throughout the class period, Reckitt Benckiser Group plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.

Get additional information about the RBGLY lawsuit: http://www.kleinstocklaw.com/pslra-1/reckitt-benckiser-group-plc-loss-submission-form?wire=3

National General Holdings Corp. (NGHC)
Class Period: August 6, 2015 to August 9, 2017
Lead Plaintiff Deadline: September 23, 2019

The lawsuit alleges that throughout the class period, National General Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (a) National General was perpetrating a massive forced-placed CPI scheme to fraudulently saddle its own customers with unwanted and unneeded automobile insurance policies that it had underwritten; (b) National General’s illicit conduct in foisting unwanted and unneeded automobile insurance on its customers had resulted in some of the victims being declared delinquent, suffering adverse impacts to their creditworthiness, and/or having their cars improperly repossessed; (c) National General was exposed to an extreme risk of regulatory scrutiny, legal risks, and reputational harm as a result of its participation in the forced placed CPI scheme; (d) the Company had failed to maintain effective internal controls over its financial reporting, including by failing to maintain formal documentation sufficient to reasonably ensure the accuracy of internal reporting and accounting procedures across much of its business, including with respect to insurance policy premiums; (e) the Company’s reported quarterly revenues and policy premiums were in part the product of a fraudulent forced-placed insurance scheme and were therefore artificially inflated and unsustainable; and (f) National General had in fact lost substantial business with Wells Fargo because Wells Fargo had terminated the forced-placed CPI scheme after concluding that it posed excessive reputational risk and legal exposure.

Get additional information about the NGHC lawsuit: http://www.kleinstocklaw.com/pslra-1/national-general-holdings-corp-loss-submission-form?wire=3

Mallinckrodt Public Limited Company (MNK)
Class Period: February 28, 2018 to July 16, 2019
Lead Plaintiff Deadline: September 24, 2019

During the class period, Mallinckrodt Public Limited Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Get additional information about the MNK lawsuit: http://www.kleinstocklaw.com/pslra-1/mallinckrodt-public-limited-company-loss-submission-form?wire=3

Evolent Health, Inc. (EVH)
Class Period: March 3, 2017 to May 28, 2019
Lead Plaintiff Deadline: October 7, 2019

The lawsuit alleges that throughout the class period, Evolent Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Evolent's partnership model was not aligned with its partners, as it was designed to parasitically increase its own revenue by extracting  enormous administrative and management fees at the expense of its partners such as Passport Health Plan ("Passport"); (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees, and money to such an extent that Passport was left on the verge of insolvency; (4) for several months, Passport was conducting a bidding process to sell itself to a financial buyer to prevent liquidation; and (5) as a result of the foregoing, Defendants public statements were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the EVH lawsuit: http://www.kleinstocklaw.com/pslra-1/evolent-health-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com